Phaseline

Targets › CPT1A

CPT1A (Carnitine O-palmitoyltransferase 1, liver isoform): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Feb 2027.

Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Also possesses a lysine succinyltransferase activity that can regulate enzymatic activity of substrate proteins such as ENO1 and metabolism independent of its classical carnitine…. (UniProt, P50416)

Open in Phaseline: the race on CPT1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sara Refaat Azab MetryTrimetazidine Dihydrochloride Tablets
Mitochondrial fatty acid oxidation inhibitor
CPT1APhase 1Diabetic Peripheral Neuropathic Pain (DPN)Feb 2027

Conditions

Diabetic Peripheral Neuropathic Pain (DPN) (1)

Modalities

small molecule (1)

Companies

Sara Refaat Azab Metry (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.